Table 4. Hepatic toxicity of immunochemotherapy.
Excluding one patient who started LDV‐SOF only after development of G4 ALT increase and HCV‐RNA flare during initial courses of R‐CHOP.
p = .02 (concurrent vs. sequential).
Excluding one patient who started LDV‐SOF only after development of G4 ALT increase and HCV‐RNA flare during initial courses of R‐CHOP.
p = .02 (concurrent vs. sequential).